Cargando…

Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression

Platinum-based chemotherapy regimens are frequently used in patients with triple-negative breast cancer (TNBC). The aim of the current study was to assess whether or not platinum-based chemotherapy is associated with an increased time to progression when compared with non-platinum-based regimens in...

Descripción completa

Detalles Bibliográficos
Autores principales:	KHALAF, DANIEL, HILTON, JOHN F., CLEMONS, MARK, AZOULAY, LAURENT, YIN, HUI, VANDERMEER, LISA, DENT, SUSAN, HOPKINS, SEAN, BOUGANIM, NATHANIEL
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919882/ https://www.ncbi.nlm.nih.gov/pubmed/24527094 http://dx.doi.org/10.3892/ol.2014.1782

Ejemplares similares

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events
por: Addison, Christina L., et al.
Publicado: (2014)

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial)
por: Hilton, John, et al.
Publicado: (2018)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Histomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients–preliminary results
por: Fralick, M., et al.
Publicado: (2012)

The use of drugs acting on the renin–angiotensin system and the incidence of pancreatic cancer
por: Mandilaras, Victoria, et al.
Publicado: (2017)

Discernment
Publicado: (1878)

Evaluation of the quality of mammographic breast positioning: a quality improvement study
por: Rouette, Julie, et al.
Publicado: (2021)

Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients
por: Beltran-Bless, A., et al.
Publicado: (2021)

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy
por: Baiomy, Mohamed Ali EL, et al.
Publicado: (2017)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
por: Joung, Eun Kyo, et al.
Publicado: (2021)

Internet chemotherapy information is of good quality: assessment with the DISCERN tool
por: Som, R, et al.
Publicado: (2012)

Platinum‐based chemotherapy for early triple‐negative breast cancer
por: Mason, Sofia RE, et al.
Publicado: (2023)

The social media context interferes with truth discernment
por: Epstein, Ziv, et al.
Publicado: (2023)

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis
por: Chen, Yimeng, et al.
Publicado: (2021)

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
por: Zhai, Xiaoyu, et al.
Publicado: (2017)

Reply: Internet chemotherapy information is of good quality: assessment with the DISCERN tool
por: Davies, E, et al.
Publicado: (2012)

Triple-Isotope Tracing for Pathway Discernment of NMN-Induced NAD(+) Biosynthesis in Whole Mice
por: Sauve, Anthony A., et al.
Publicado: (2023)

Commentary: Discerning the porhyrias!
por: Murugan, S Bala
Publicado: (2018)

Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Zhu, Yunshu, et al.
Publicado: (2020)

The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer
por: Vernieri, Claudio, et al.
Publicado: (2018)

Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis
por: LIU, MIAO, et al.
Publicado: (2013)

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer
por: Chen, Yimeng, et al.
Publicado: (2023)

Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer
por: Collier, Katharine A., et al.
Publicado: (2021)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

A disCERNing grid
por: Ahuja, A
Publicado: (2000)

Discerning Disparities: The Data Gap
por: Treadwell, Henrie M., et al.
Publicado: (2018)

A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer
por: Dent, Susan, et al.
Publicado: (2021)

A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer
por: Fernandes, Ricardo, et al.
Publicado: (2023)

De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologists
por: Hutton, Brian, et al.
Publicado: (2013)

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing
por: Galland, Loïck, et al.
Publicado: (2022)

Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer
por: Gomez Marti, Juan Luis, et al.
Publicado: (2022)

Discerning Pig Screams in Production Environments
por: Vandermeulen, J., et al.
Publicado: (2015)

Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer
por: Hale, J P, et al.
Publicado: (2002)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Detection of PIK3CA Mutations in Breast Cancer Bone Metastases
por: Daneshmand, Manijeh, et al.
Publicado: (2012)

Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Lu, Fei, et al.
Publicado: (2021)

Effectiveness of Platinum-Based Treatment for Triple Negative Metastatic Breast Cancer: a Meta-Analysis
por: Kaya, Vildan, et al.
Publicado: (2018)

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
por: Bonnet, Elise, et al.
Publicado: (2022)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
por: Grande, Enrique, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_levqc0e8e54f9ju6j3qrum5iem